Is tucatinib a chemotherapy drug?

Tucatinib is not a chemotherapy drug, but a targeted drug.

Tucatinib is a targeted drug, specifically a tyrosine kinase inhibitor (TKI). It blocks the growth and spread of breast cancer cells mainly by inhibiting the activity of human epidermal growth factor receptor 2 (HER2). Different from chemotherapy drugs, targeted drugs have higher specificity and can attack the unique molecular targets of cancer cells to reduce damage to normal cells.

Tucatinib is mainly used to treat HER2 -positive advanced or metastatic breast cancer, especially for patients who have received one or more anti-HER2 treatment regimens. In addition, tucatinib is approved in combination with trastuzumab for the treatment of HER2-positive metastatic colorectal cancer.

In terms of usage and dosage, tucatinib is usually administered orally, and the recommended dose is 300mg (mg) twice daily. Patients should try to take it at the same time every day to ensure a stable concentration of the drug in the body. At the same time, doctors will adjust the dose based on the patient's specific condition and the severity of adverse reactions.

Multiple clinical studies have confirmed the efficacy and safety of tucatinib in the treatment ofHER2 positive advanced breast cancer. Compared with chemotherapy alone, combined use of tucatinib can prolong progression-free survival and overall survival. However, tucatinib may also cause some side effects during use, such as diarrhea, abnormal liver function, and cardiotoxicity. Therefore, before using tucatinib, patients need to fully understand its efficacy and risks and conduct treatment under the guidance of a doctor.

References:

https://breastcancernow.org/about-breast-cancer/treatment/targeted-biological-therapy/tucatinib-tukysa/